Scope of the Study
The global T-cell Immunotherapy market is expected to boost the global demand in the forecasted period due to the growing demand for better cancer treatment in cancer in children is escalating the growth of the T-cell immunotherapy market. T-Cell Immunotherapy is a type of treatment in which a patient’s T cells (a type of immune cell) are changed in the laboratory so they will bind to cancer cells and kill them. The global and regional prevalence of major types of cancer for which T-cell Immunotherapy is used is highlighted in the report. These cancers include leukemia, lymphoma, melanoma, ovarian cancer, and bladder cancer amongst others.
The market study is being classified by Type (Active Immunotherapy and Passive Immunotherapy), by Application (Stomach Cancer, Lung Cancer, Colorectal Cancer, Esophagus Cancer, Pancreatic Cancer and Others) and major geographies with country level break-up. According to AMA, the Global T-Cell Immunotherapy market is expected to see growth rate of 16.42%
Novartis AG (Switzerland), Gilead Sciences (United States), bluebird bio (United States), TCR2 Therapeutics Inc. (United States), Sorrento Therapeutics (United States), Fate Therapeutics (United States), Merck KGaA (Germany), Pfizer (United States) and Amgen (United States) are some of the key players profiled in the study.
With the approval of Kymriah and Yescarta, several companies have shifted their business models from developing small molecule and protein-based therapies to adoptive T cell therapy. A range of market entities, from new entrants to the well-established pharma companies are exploring the therapy, which is anticipated to intensify the competition as multiple companies are receiving approvals and consequently gearing up their manufacturing capabilities. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global T-Cell Immunotherapy market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global T-Cell Immunotherapy market by Type, Application and Region.
On the basis of geography, the market of T-Cell Immunotherapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2019. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- High Demand due to Clinical Success and Accelerated Product Approvals
- The Growing Prevalence of Cancer
- Growing Network of Diverse CAR-T/TCR Developers with Their Offerings would Reshape the Engineered T cells Market Landscape
- The Rising Preference for the Gene Therapies in the Cancer Treatment
- The Rising Concern with The Side Effects
- Increasing Investments by Government Bodies
- Growing Technological Advancements in the field of Immunotherapy
- The Stringent Government Regulation associated with T-Cell Immunotherapy
Tocilizumab (Actemra®) is approved for the treatment of adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS). and Tisagenlecleucel (KymriahTM) is FDA approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Kymriah is also approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
Key Target AudienceT-Cell Immunotherapy Providers, Government Regulatory Bodies, Private Research Organizations, Government Research Organizations and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase